The ability of adenovirus vectors to accomplish efficient of FGF2 to the Fab. Also, this system will allow for the facile conjugation of other ligands to the Fab by the fact in vivo gene transfer has made them attractive for use in a number of gene therapy strategies. 1 However, the that the boronic acid group attached to the Fab would be utilized for all ligands, while the hydroxamic acid group inability of these vectors to target specific cell types has prevented them from achieving their full potential. In this could be attached to the specific ligand of interest. In this article, we describe the conjugation of an Nregard, a number of recent studies have focused on altering adenovirus tropism to target them in vitro to cells hydroxysuccinimide (NHS) derivative of phenylboronic acid (PBA) to the Fab fragment and an iodoacetamido expressing certain receptors. [2] [3] [4] [5] [6] [7] These studies have shown that the targeting of adenovirus vectors through tropism derivative of dihydroxybenzohydroxamic acid (DHBHA) to a mutein of FGF2 in which the cysteine at position 96 modifications is feasible, potentially increasing their utility in a number of gene therapy applications.
is substituted with a serine. 8 The PBA and DHBHA moieties form a complex which is stable in the pH range 2.5-We have previously altered adenovirus tropism by utilizing the Fab fragment of a neutralizing anti-knob anti-11.5 and are used to form the Fab-PBA-DHBHA-FGF2 conjugate (US Patent Number: 5,594,151). FGF2 was body (1D6.14), which ablates native adenovirus tropism, conjugated to folic acid for targeting to folate receptorchosen as a ligand because high-affinity FGF receptors are found on a number of malignant cell lines as well as positive tumor cells. 5 The conjugation of the Fab to folic acid employed a straightforward amino to carboxy on proliferating endothelial cells found in tumor vasculature. 9 In addition, FGF2 has been used to target toxin chemical conjugation. In contrast, the Fab was conjugated to the basic fibroblast growth factor (FGF2) utilizing a molecules and DNA to high-affinity FGF receptors both in vitro and in vivo. [10] [11] [12] [13] [14] [15] The Fab-PBA and FGF2-DHBHA more difficult procedure in which the Fab was derivatized to contain free sulfhydryls which were then reacted were structurally and functionally validated and then used to target an adenovirus vector encoding the firefly with the sulfhydryl on the FGF2.
6,7 The present study utilized a novel cross-linking system for conjugating FGF2 luciferase gene (AdCMVLuc) to Swiss 3T3 mouse fibroblast cells in vitro. In addition, the Fab and FGF2 derivato the anti-knob Fab by the reaction of a boronic acid moiety with a hydroxamic acid. This cross-linking system tives were used to target AdCMVLuc to human FGF receptor-positive tumor cell lines (PANC-1, SKOV3.ip1 was employed because the chemistry involved is not as difficult as the chemistry used in the direct conjugation and D54 MG The PBA NHS ester was dissolved in dimethylform- shoulder at 300-340 nm, consistent with DHBHA conjugation. Thus, the conjugations of the PBA to the Fab and the DHBHA to the FGF2 were relatively simple and alterthat 5 g of Fab-PBA inhibited Ad infection to the same extent as 5 g of Fab (Ͼ98%) and that 1 g of Fab-PBA nate ligands with free sulfhydryls could be conjugated to DHBHA in a similar manner for complexation to the Fabinhibited Ad infection by 94% (Figure 1a) . Therefore, 2 g of the Fab-PBA were used per 4 × 10 7 plaque forming PBA conjugate.
The Fab-PBA conjugate was characterized by determinunits (p.f. counted in a gamma counter. This showed that the DHBHA-FGF2 inhibited binding of I-125-labeled FGF2 to The ability of Fab-PBA to inhibit adenovirus infection through binding of the fiber knob was confirmed using the cells to the same extent as FGF2 alone, thus confirming that the FGF2 in the conjugate still bound to AdCMVLuc and a human nasopharyngeal carcinoma cell line, KB. Various concentrations of the Fab-PBA conju-FGF receptors. An ELISA was performed to ensure that the PBA and gate or the Fab alone were incubated with AdCMVLuc at room temperature for 30 min and then added to KB DHBHA moieties in the Fab-PBA and DHBHA-FGF2 conjugates could still bind to each other. Recombinant cells. After 1 h, the cells were supplemented with media and assayed for luciferase activity 24 h later. The value Ad5 knob protein was plated on Ni-NTA strips and probed with the Fab-PBA and DHBHA-FGF2 conjugates. obtained from the luciferase assay is directly proportional to the number of infecting viral particles. This showed
The amount of FGF2 bound to the plate was then meas-ured by absorbance after addition of a primary polyoccurring, although the efficiency of this coupling is not determined. In comparison, low levels of binding were clonal anti-FGF2 antibody and a secondary goat antirabbit antibody conjugated to horseradish peroxidase.
observed when DHBHA-FGF2 and Fab-PBA were added alone or when unconjugated Fab was added followed by Incubation of Fab-PBA with Ad5 knob for 1 h at room temperature followed by addition of DHBHA-FGF2 DHBHA-FGF2 (absorbance = 0.17, 0.19 and 0.22, respectively). resulted in an absorbance of 0.75 (Figure 2 ). When the Fab-PBA and DHBHA-FGF2 were first incubated
The schema for targeting AdCMVLuc to FGF receptorpositive cells with Fab-PBA and DHBHA-FGF2 is shown together for 30 min and then added to Ad5 knob, the absorbance was 1.25. This difference is likely due to a in Figure 3 . The amount of Fab-PBA required to neutralize AdCMVLuc infection was incubated with higher coupling efficiency between PBA and DHBHA when pre-incubated at a higher concentration. This conAdCMVLuc followed by the addition of various concentrations of DHBHA-FGF2. The complexes were then firms that the coupling between the PBA and DHBHA is added to 3T3 cells and luciferase expression determined tor binding in the presence of an excess of FGF2 (Table  1) . Adenovirus infection using Fab-PBA and DHBHA-24 h later. The Fab-PBA conjugate inhibited AdCMVLuc expression (16 000 relative light units (RLU)/g) by FGF2 was inhibited by Ͼ63% for all cell lines when excess FGF2 was added to the cells before infection. Thus, Ͼ98% (250 RLU/g). The addition of increasing amounts of DHBHA-FGF2 to the Ad-Fab-PBA complex resulted in Fab-PBA and DHBHA-FGF2 can be used to deliver adenovirus vectors to a number of tumor cell lines a dose-dependent increase in luciferase expression. At the highest dose, there was a greater than 100-fold increase of through FGF receptors. Modification of adenovirus tropism has been the focus luciferase expression than when cells were infected with AdCMVLuc alone (Figure 4) . Redirection of adenovirus of many recent studies. In particular, immunological methods have been employed either to expand adenoto FGF receptors was demonstrated by the addition of an excess of FGF2 to the cells before infection which virus tropism to permit the infection of cells that are refractory towards native adenovirus infection 2, 3 or to inhibited luciferase expression by Ͼ98% (Figure 4) . When AdCMVLuc was incubated with unconjugated Fab and limit adenovirus tropism in order specifically to target adenovirus to a particular cell type. 5 In the latter regard, then with DHBHA-FGF2 there was an increase in luciferase expression when compared with AdCMVLuc infecour group has previously shown that conjugation of folic acid to a neutralizing anti-knob antibody fragment (Fab) tion alone which is likely due to some nonspecific interactions between the DHBHA and the Fab or the adenovirus yielded a conjugate (Fab-folate) that specifically mediated adenovirus infection of folate receptor-positive tumor protein coat. This nonspecific interaction may not be unexpected as the DHBHA may undergo an ion cells in vitro. 5 We hypothesize that utilization of the crosslinking method described here for rapidly attaching variexchange reaction with the Fab or the viral proteins. Thus, we have demonstrated that the Fab-PBA and ous ligands to the Fab will result in specific targeting of adenovirus to other desired tumor cell types. DHBHA-FGF2 conjugates can be used to redirect adenovirus to FGF receptors.
In the present article, a novel method for linking a ligand (FGF2) to the Fab fragment was demonstrated.
We then sought to demonstrate that the Fab-PBA and DHBHA-FGF2 could be used to deliver AdCMVLuc to This system is analogous to the biotin-streptavidin system and may confer advantages over biotin-streptavidin various human tumor cell lines via FGF receptors. To this end, we investigated PANC-1, SKOV3.ip1 and D54 MG by virtue of the low molecular weight components, which may be less immunogenic and easier to produce cells. The optimal amounts of Fab-PBA and DHBHA-FGF2 used to target AdCMVLuc to FGF receptors for clinical use. After conjugation of PBA to Fab and DHBHA to FGF2, the conjugates were characterized both expressed on Swiss 3T3 cells were used for targeting AdCMVLuc to FGF receptors expressed on PANC-1, structurally and functionally. The validated conjugates were then utilized in an ELISA assay to confirm that the SKOV3.ip1 and D54 MG cells. The Fab-PBA conjugate was able to inhibit adenovirus infection by Ͼ92% for each PBA-DHBHA complex still formed. Optimization of AdCMVLuc infection using the conjugates was perforof the cell lines. Use of the DHBHA-FGF2 conjugate greatly enhanced luciferase expression in the SKOV3.ip1 med in Swiss 3T3 cells and these conditions applied toward the infection of a variety of other human tumor cells when compared with AdCMVLuc alone (Ͼ12-fold increase), while the luciferase expression was restored to cell lines in vitro. This method can now be applied towards the conju-79 and 74% of the level achieved with AdCMVLuc alone in the PANC-1 and D54 MG cells, respectively. It is diffigation of other ligands to the Fab for targeting adenovirus to various tumor cell types in a relatively rapid cult to correlate the differences in gene transfer between the cell lines because of the complicated adenoviral bindmanner. These ligands may consist of antibodies, singlechain antibodies, growth factors, cytokines or peptides. ing and entry mechanisms involved. The specificity for FGF receptors was demonstrated by inhibition of recepThus, a wide array of proteins have potential value for PANC-1, human pancreatic carcinoma cells were obtained from the ATCC and SKOV3.ip1 human ovarian adenocarcinoma cells were obtained from Janet Price (Baylor University). Both cell lines were maintained in DMEM supplemented with 10% FCS and 2 mm lglutamine. The D54 MG human glioma cells are a derivative of the A172 cell line established by Giard et al, 17 Bigner et al 18 and Goldman et al 19 and were maintained in DMEM/F12 supplemented with 7% FCS and 2 mm l-glutamine. The cells were infected as described in Figure 4 with only the 160 pmol concentration of DHBHA-FGF2 being used for targeting. Inhibition studies were conducted by adding 20 g of FGF2 to each well immediately before addition of the Ad-FGF2 complex. The data represent RLU/g of protein and standard deviations are in parentheses.
